Home > Insider Trading > Filing (0000899243-20-000395)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1631650	Aimmune Therapeutics Inc.	AIMT	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1222037	Md C Daniel Adelman	Aimmune Therapeutics, Inc. 8000 Marina Boulevard, Suite 300 Brisbane CA 94005-1884	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.0001 Par Value	Acquisiton	2020-01-02	20,000	$19.63	41,250	No	4	M	Direct
Common Stock, $0.0001 Par Value	Disposition	2020-01-02	20,000	$35.00	21,250	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2020-01-02	20,000	$0.00	20,000	$19.63

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
70,000		2027-02-24	No	4	M	Direct

Footnotes

The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
Includes 11,875 restricted stock units ("RSUs") which will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
Includes 9,375 RSUs which will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
Represents the weighted average sale price for the entire number of shares sold. The sale prices range from $34.99 to $35.04 per share. Information on the actual numbers of shares sold at each sale price can be obtain from the Issuer upon request.
The shares subject to the option will vest and become exercisable as to one-forty-eighth (1/48th) of the total number of shares subject to the option in successive, equal monthly installments measured from February 24, 2017, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.